A LITERATURE REVIEW: EFFECTS OF CLONAZEPAM USE IN PREGNANCY ON THE RISK OF BIRTH MALFORMATIONS

By

Md Yamin Ullah Sarker

19146008

A thesis submitted to the School of Pharmacy in partial fulfillment of the requirements for the degree of
Bachelor of Pharmacy

School of Pharmacy
BRAC University
January 2026

Declaration

It is hereby declared that

1. The thesis submitted is my/our own original work while completing degree at BRAC University.
2. The thesis does not contain material previously published or written by a third party, except where this is appropriately cited through full and accurate referencing.
3. The thesis does not contain material which has been accepted, or submitted, for any other degree or diploma at a university or other institution.
4. I/We have acknowledged all main sources of help.

Student's Full Name & Signature:

Md Yamin Ullah Sarker
19146008

Approval

The thesis titled “A Literature Review: Effects of Clonazepam Use in Pregnancy on The Risk of Birth Malformations” submitted by Md Yamin Ullah Sarker (19146008) of Spring, 2023 has been accepted as satisfactory in partial fulfillment of the requirement for the degree of Bachelor in Pharmacy on

Examining Committee:

Supervisor:
(Member)

_____

Mohd. Raeed Jamiruddin, PhD
Associate Professor, School of Pharmacy
BRAC University

Program Coordinator:
(Member)

_____

Full Name
Designation, Department
BRAC University

Departmental Head:
(Chair)

_____

Professor A F M Yusuf Haider, PhD
Acting Dean, School of Pharmacy
BRAC University

Ethics Statement

This literature review was conducted in compliance with the academic and ethical standards prescribed by BRAC University. The study is entirely based on secondary data obtained from previously published and publicly available sources, including peer-reviewed journal articles, textbooks, and recognized scientific reports related to the use of clonazepam during pregnancy and the risk of birth malformations.

The study did not involve any primary data collection, human participants, animals, clinical trials, or access to confidential or identifiable patient information. Therefore, ethical approval from the Institutional Review Board (IRB) or any ethics committee of BRAC University was not required for this research.

All sources of information used in this review have been appropriately cited in accordance with academic referencing guidelines to ensure transparency and to avoid plagiarism. The study was conducted with due consideration for academic integrity, objectivity, and responsible research practice, and the findings have been presented accurately without bias, fabrication, or misrepresentation.

Abstract

Psychotropic drugs such as benzodiazepines are often prescribed to treat anxiety, depression, or seizure disorders, as pregnancy presents distinct physiological and psychological challenges. Clonazepam is one such medication frequently prescribed for its anticonvulsant and anxiolytic properties; however, its safety during pregnancy remains uncertain due to concerns about placental transfer and fetal exposure. Through a systematic literature review, this study aims to evaluate the relationship between Clonazepam use during pregnancy and the risk of congenital malformations. A detailed literature search was conducted using databases including PubMed, ScienceDirect, Scopus, ResearchGate, Google Scholar, and Medline, focusing on studies published between 2000 and 2025. Both clinical and observational studies involving pregnant women exposed to Clonazepam or similar benzodiazepines were included for consideration. Records of dosage, exposure duration, maternal characteristics, and fetal outcomes were extracted and assessed for quality in accordance with PRISMA and Newcastle–Ottawa Scale guidelines. The results showed that using clonazepam alone while pregnant is not strongly linked to major birth defects, which means there is a low risk of teratogenesis. However, sporadic instances of microcephaly and minor neurodevelopmental consequences in polytherapy exposures underscore the necessity for prudent therapeutic application. Although, the overall teratogenic risk remains inconclusive, the available evidence suggests a possible association between Clonazepam exposure and increased risks of low birth weight, preterm birth, and mild congenital anomalies. The study emphasizes the need for cautious clinical use and further large-scale research to clarify the safety of Clonazepam during pregnancy.

Keywords: Clonazepam, Congenital malformations; Teratogenic risk, Fetal exposure; Placental transfer; Neurodevelopmental, Preterm birth

Acknowledgement

First and foremost, I want to express our gratefulness to Almighty Allah for providing us with the ability and strength necessary to complete this project work successfully.

I am grateful to my supervisor Associate Professor Dr. Mohd. Raeed Jamiruddin, PhD, School of Pharmacy, for his worthiest guidance and incessant support throughout my thesis which directed me to gain all the precious knowledge in an innovative way. Both of his leadership abilities and the breadth of knowledge contributed to our success in finishing the project in a proficient way.

My sincere gratitude is extended Professor Dr. A F M Yusuf Haider, PhD, Acting Dean, School of Pharmacy for his valuable advice and unwavering support, which enabled me to complete the project in a timely and systematic manner.

My gratitude finds a way towards School of Pharmacy officials. I appreciate their co-operation, assistance & valuable advice, they shared within the scope of their abilities. Furthermore, I am grateful to my parents and admire their immense blessing, love and support. Finally, I would like to acknowledge that I are still accountable for the shortcomings and mistakes that undoubtedly still exist.

Table of Contents

List of Tables

List of Figures

List of Acronyms

BZD	Benzodiazepine
CNS	Central Nervous System
MCM	Major Congenital Malformation
MM	Major Malformation
SSRI	Selective Serotonin Reuptake Inhibitor
AED	Antiepileptic Drugs
CLN	Clonazepam
NOS	Newcastle–Ottawa Scale
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Chapter 1
INTRODUCTION

1.1.Background

One of the most significant life events is pregnancy, which for women expecting their first child signifies a difficult shift from one way of living to another. During pregnancy, transient mental health issues are very common. Approximately one in two women will eventually have symptoms of anxiety, and one in two will experience symptoms of depression (Kent, 2011). Pregnant women are often administered psychotropic medications, such as antipsychotics, anxiolytics, sedatives/hypnotics, and antidepressants (Houben et al., 2020). In the United States, more than 10% of expectant mothers received at least one psychiatric medication between 2006 and 2011(Hanley & Mintzes, 2014). Between 1994 and 2003, the prescription rates for antipsychotics and antidepressants during pregnancy ranged from 0.09 to 0.19 (per 1000 women) in the Netherlands, while the range for anxiolytics and sedatives/hypnotics was 0.09 to 0.15 (Bakker et al., 2006). When choosing whether to start, continue, or discontinue psychiatric therapy while pregnant, it's critical to weigh the possible dangers and advantages for the mother and unborn child (Robiyanto et al., 2023). If the advantages of administering a psychotropic treatment during pregnancy outweigh any potential risks, the safest and most effective dosage for the mother should be used (Orsolini & Bellantuono, 2022). The use of psychiatric medications during pregnancy has been linked to numerous negative gestational and neurodevelopmental outcomes (Andrade, 2021a). Numerous studies have looked at the risk of major congenital malformations to fetal exposure to antipsychotic medications over the last one to two decades (Andrade, 2021b). Monitoring the fetus during pregnancy and treating the mother's mental health condition can guarantee that the right steps are taken to provide more than enough care during these trying times, regardless of the treatment plan (Edinoff et al., 2022). In some cases, pregnant women may be prescribed benzodiazepines and benzodiazepine-related medications (z-drugs), sometimes known as sedatives, to alleviate anxiety and sleep issues (Chan et al., 2023). When compared to no exposure, exposure to benzodiazepines and benzodiazepine-related drugs during pregnancy was linked to a higher risk of congenital malformation, cardiac malformation, and preterm birth (Wu et al., 2024). In this study, we are assessing the use of a benzodiazepine drug commonly known as Clonazepam during pregnancy and evaluating the risk of fetal malformation.

1.2. Scopes

The study aims to assess the use of Clonazepam during pregnancy and evaluate the risk of fetal malformation. The study focuses on congenital malformation of the fetus during pregnancy due to the use of psychotropic drugs. The study considered important factors such as dimensions, column type, section type, height, unit weight, and thickness. This work aims to systematically examine and synthesize existing research on the use of Clonazepam during pregnancy with a particular focus on its teratogenic potential and risk of fetal malformations. The scope encompasses both clinical and preclinical studies, covering various research designs including observational studies, case reports, retrospective cohort studies, and meta-analyses.

1.3.Objectives

General Objective: The primary goal of this study is to review and analyze existing literature on the use of Clonazepam during pregnancy, focusing on its potential to cause fetal malformations.

Specific Objectives:

- To compare the teratogenic risk of Clonazepam with other benzodiazepines used in pregnancy, identifying any unique risks or relative safety.
- Asses the pharmacological profile of Clonazepam, including its mechanism of action, placental transfer, and metabolism during pregnancy.
- To summarize current clinical guidelines and recommendations on Clonazepam use in pregnant women.

1.4.Research Questions

The primary research topic of this thesis addresses: *What is the relationship between maternal use of Clonazepam during pregnancy and the risk of fetal malformations?* The research investigates several connected topics to fully answer this question. It investigates how the teratogenic risk of Clonazepam compares to that of other benzodiazepines commonly used in pregnant populations. This includes identifying whether Clonazepam presents any unique risks in terms of fetal malformation or if it offers a relatively safer profile within the benzodiazepine class. To contextualize these risks, the study also seeks to assess the pharmacological characteristics of Clonazepam, including its mechanism of action, the extent of its placental transfer, and how its metabolism may be altered during pregnancy. Understanding these pharmacokinetic and pharmacodynamic aspects is essential to evaluating potential fetal

exposure and susceptibility. Additionally, this work aims to examine and synthesize current clinical guidelines and regulatory recommendations regarding the use of Clonazepam in pregnant women. It seeks to determine whether these recommendations are consistent with the existing evidence and whether they provide adequate guidance for risk management in clinical settings. Together, these research questions aim to contribute to a more informed and evidence-based approach to the use of Clonazepam during pregnancy.

Chapter 2

LITERATURE REVIEW

In this section, we are going to review benzodiazepines and benzodiazepine-related medications, Clonazepam usage and pharmacokinetics, and the effect of Clonazepam during pregnancy. The research gaps addressed in this work will be identified.

2.1. Benzodiazepines and Related Drugs

Benzodiazepines (BZDs) are a class of psychoactive drugs characterized by their depressant effects on the central nervous system (CNS). which have sedative effects and swiftly permeate the blood–brain barrier in order to modulate the activity of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) (Edinoff et al., 2021). The GABA-A subunit has six different isoforms. BZDs primarily target the GABA-A receptor subunit (Griffin et al., 2013a). The alpha (A) subunit is the most significant among the various subunits of the GABA-A receptor. The effects of benzodiazepines (BZDs) on the central nervous system are determined by the different isoforms of the alpha subunit. The sedative effects, anterograde amnesia, and some of the anticonvulsive actions of diazepam are thought to be effective due to the A1 subunit. The anxiolytic and myorelaxant actions are mediated by the A2 subunit isoform. BZD binds between the alpha and gamma subunits, to be precise about binding locations and effects. It makes GABA more effective at the GABA-A receptor, enabling it to have a greater impact (Campo-Soria et al., 2006).



Figure 2.1 Structure of Benzodiazepines

2.1.1. The Effects of Benzodiazepine on Cognition

In a prospective longitudinal study on how psychotropic medications affect older people's cognitive abilities found no significant long-term effect of BZD use on cognition.(Allard et al., 2003).Comparing the effects of long-term BZD usage to those of high dosage, the former causes a slight but noticeable shift in fluid intelligence, while the latter is associated with severe cognitive deterioration(Bierman et al., 2007).

2.1.2. Side Effects of Benzodiazepine Use

There are several noteworthy adverse effect profiles associated with BZDs. Elderly BZD users over 80 years of age had a significantly higher risk of falls that result in injury, whereas patients under 80 do not have a significantly higher risk (Pariente et al., 2008). However, premature birth and low birth weight are risks for women who use BZD during pregnancy. Although the study revealed some teratogenic effects of BZDs on babies, the findings are not statistically significant, and some of the studies resulted in congenital malformations from the use of other drugs(Wikner et al., 2007a).

2.1.3. Misuse of Benzodiazepine

It has been shown that women receive prescriptions more often than men, they are more vulnerable to BZD usage. According to reports, women are more likely than men to be diagnosed with anxiety and stress problems, which may account for the differences in prescriptions for men and women (McLean et al., 2011). The majority of research participants cited coping as the cause of their BZD prescription abuse. Although their study revealed that white people are more likely than Black, Hispanic, and Asian people to abuse BZD because white patients receive more prescriptions than other races, Cook et al. also supported the finding that there is no gender-based difference in BZD misuse(Cook et al., 2018).

2.1.4. Issues with Clinical Use of Benzodiazepine

BZDs are categorized based on their potency or duration of effect. The clinical usefulness of the medications is determined by the differences in these attributes. Low-potency benzodiazepine medications include Oxazepam, Temazepam, and Chlordiazepoxide, which have low levels of toxicity and are well tolerated. In addition to being utilized as adjuncts for the treatment of numerous other illnesses, Alprazolam, Lorazepam, and Clonazepam are highly effective therapeutic medications for treating panic disorders. With BZD, proper care is required due to its harmful effects on the central nervous system. While BZDs only temporarily impair implicit memory, they cause long-term impairment of episodic implicit memory.

Additionally, they cause disinhibition, which makes it harder for the user to recognize dangerous behaviors or acts. If an elderly patient in intensive care is on a BZD, they may have delirium(Griffin et al., 2013b). The expression of mRNA transcripts that are essential for controlling synapses and plasticity, including CaMKIIa, BDNF, GIF, c-fos, and NGFIa, is similarly decreased. Diazepam's reduction of CaMKIIa has a long-lasting effect that reduces GABA-A receptor sensitivity and limits the neuron's response to intracellular calcium changes(Huopaniemi et al., 2004).

2.1.5. Withdrawal amongst the Elderly

Although withdrawal may be hazardous for everyone, four major groups are more vulnerable to the possibly fatal risks associated with BZD dependence. First, regardless of BZD use, older adults (over 65) are at a very high risk because of their propensity for falls, confusion, insomnia, memory loss, and other mental health issues. The areas of the brain linked to different sleep patterns and behaviors shrink as people age, which frequently leads to less restful sleep, an inability to sleep for extended periods, and a decrease in the production of sleep spindles during non-REM sleep, which is essential for memory consolidation and the retention of new information(Stewart, n.d.). Chronic BZD use for sleep alleviation may be more common among the elderly due to these sleep abnormalities and their inclination for insomnia. However, using BZD in the elderly is extremely risky due to the possibility of psychomotor slowness, amnesia, and increased forgetfulness as adverse effects. Some people have even demonstrated a difficulty to return to their cognitive baseline when they stop using something after longer than two weeks. It has been linked to a higher risk of dementia(Billioti De Gage et al., 2014; Reeves & Kamal, 2019). In considering this, it is recommended that withdrawal symptoms be carefully managed with a BZD long-acting taper, gradually lowering dosages over time, in addition to psychotherapy approaches such as cognitive behavioral therapy (CBT) with psychoeducation and motivational enhancement(Birchley, 2009).

2.1.6. Withdrawal amongst the Children

Second, it has been demonstrated that 20% of the children in the intensive care unit who received BZD during sedation—more precisely, midazolam—show signs of withdrawal. The duration of the infusion and the overall dosage determine how severe the withdrawal symptoms are; they typically manifest as anxiety, tremors, trouble sleeping, and uncontrollable weeping(Pecknold et al., 1982).

2.1.7. Withdrawal amongst the Pregnant Women and the Fetus

Both pregnant women and fetuses are more susceptible to the negative effects of withdrawal because BZD metabolizes slowly in both cases and can cross the placenta to cause concentrations in the newborn to rise to dangerous levels(Authier et al., 2009). Use during pregnancy has been associated with low birth weight, premature labor, and intrauterine growth restriction, while a therapeutic dose is not teratogenic. Muscle laxity, inability to breastfeed, and excessive drowsiness are the hallmarks of "floppy infant syndrome," which the fetus is most susceptible to. The infant exhibits withdrawal symptoms, including persistent feeding difficulties, high-pitched crying, hyperexcitability, and potentially failure to thrive, about two weeks after delivery. The main worry is that these fetuses may eventually be at risk for attention deficit disorder, autism, learning disabilities, and general hyperactivity(Wikner et al., 2007b).

2.2 Clonazepam

A long-acting benzodiazepine with an intermediate onset, clonazepam, is frequently used to treat seizures, severe anxiety, and panic disorders. Clonazepam is a 1-4 benzodiazepine that strengthens the GABA inhibitory effect by increasing chloride ion penetration and, consequently, membrane polarization. This molecule contains the common pharmacological activities of this class, including myorelaxant, anxiolytic, sedative, hypnotic, anti-convulsive, and amnesic. The main therapeutic indications for the oral form include the treatment of generalized epilepsy either as a temporary monotherapy or in combination with other anti-epileptic treatments; the injectable version is only used in cases of acute epilepsy(Debruyne et al., 2010).



Figure 2.2 Structure of *Clonazepam*

2.2.1. Mechanism of Action

Clonazepam is a highly effective long-acting benzodiazepine. Clonazepam causes pharmacological effects by acting as a positive allosteric modulator of GABA-A receptors. The GABA-A receptor is a ligand-gated chloride ion channel whose endogenous ligand is GABA (gamma-aminobutyric acid). Benzodiazepines promote GABA-A activity by increasing the frequency of chloride channel opening, resulting in cell hyperpolarization and decreased firing, causing calming effects on the brain by reducing neuron excitability. In the absence of GABA, benzodiazepines have no effect on GABA-A receptor activity(Sigel & Steinmann, 2012).

GABA is an inhibitory neurotransmitter found abundantly in the brain and limbic system. There are three GABA receptors: A, B, and C. However, BZDs exclusively affect GABA-A receptors. Each receptor complex has two GABA-binding sites and one BZD-binding site, and it is made up of five subunits: two alpha, two beta, and one gamma. BZDs do not bind to the same receptor site on the receptor complex as the natural neurotransmitter GABA, but rather to unique BZD-binding sites at the interface of the alpha and gamma subunits. The binding causes a conformational change in the GABA-A receptor's chloride channel, resulting in cell hyperpolarization and accounting for GABA's inhibitory impact throughout the central nervous system(Griffin et al., 2013c).

GABA receptors are further categorized into different BZD receptors based on the alpha subunit isoforms. The cerebral cortex, thalamus, and cerebellum are densely packed with benzodiazepine type-1 receptors (BZ1), which include alpha-1 subunits and are responsible for the anticonvulsant and sedative effects. The anxiolytic effects of BZDs are mediated by benzodiazepine type-2 receptors containing alpha-2 subunits, which are predominantly found in the limbic system, motor neurons, and dorsal horn of the spinal cord(Basit & Kahwaji, 2025).

2.2.2. Pharmacokinetics

Absorption: Clonazepam is rapidly absorbed after oral dosing. The maximum plasma concentration is attained between one and four hours after oral treatment.

Distribution: Clonazepam is roughly 85% bound to plasma proteins. Clonazepam has lesser lipid solubility than other high-potency benzodiazepines, making it less likely to cause anterograde amnesia.

Metabolism: Clonazepam is substantially metabolized by the liver's cytochrome P450, namely CYP3A, in a dose-dependent manner.

Excretion: Clonazepam has an elimination half-life of around 30 to 40 hours. Clonazepam's principal metabolite, 7-amino-clonazepam, is primarily eliminated in the urine(Kacirova et al., 2016).

2.2.2.1 Teratogenic potential of Benzodiazepine

The literature on benzodiazepine usage during pregnancy is characterized by accounts of fetal abnormalities. However, some studies have revealed that neonates exposed to benzodiazepines in utero are more likely to suffer respiratory problems, especially if the exposure occurs late in gestation. This conclusion is consistent with our previous discovery that newborns exposed to benzodiazepines require more ventilatory assistance, however this was not as common. Research suggests a link between benzodiazepine usage during pregnancy and preterm birth, but there are some inconsistencies (Calderon-Margalit et al., 2009; Källén & Reis, 2012) The gestation period was barely shortened by 3.6 days, and they primarily had early exposures to benzodiazepines. The association between late benzodiazepine usage and the risk of preterm birth in other studies may be explained by indication-specific confounding. Benzodiazepines for anxiety related to obstetrical risks may have been prescribed to women who experienced pregnancy problems. On the other hand, the risk of pre-term delivery may be higher with benzodiazepine treatment close to delivery than with early treatment.

Although apoptosis was found in the central nervous system, it is unclear if this result also applies to embryonic membranes. γ-Amino butyric acid agonists have the ability to cause apoptosis, which might conceivably weaken fetal membranes.

According to other research, the use of benzodiazepines by mothers is associated with the birth of a child with a low birth weight (Yonkers et al., 2017).

Chapter 3

METHODOLOGY

This section outlines the research design and methodology employed in the study. The steps involved in identify.

3.1 Research Design

This study was conducted as a literature review to assess the relationship between the use of clonazepam in pregnant women and their risk of congenital malformations. The review study followed a systematic approach to collect, select, identify and synthesize information from peer reviewed publications. The teratogenic risk of clonazepam and other benzodiazepines were emphasized by direct evaluation in both human subjects and clinical trials.

3.2 Data Sources

An extensive search was undertaken across multiple scientific databases to ensure broad coverage of existing materials. The primary databases included:

- PubMed
- ScienceDirect
- Scopus
- ResearchGate
- Google Scholar
- Medline

Furthermore, the relevant studies and review articles were manually screened to identify related publications.

3.3 Search Strategy

The search for literature employed a combination of keywords and Medical Subject Headings (MeSH) terms. The search keywords were conjured to capture studies related to clonazepam, benzodiazepines, pregnancy, and malformations. Key search terms included:

- Clonazepam
- Benzodiazepines/BZD
- Pregnancy
- Pregnancy Malformations
- Congenital malformations

- Teratogenicity
- Birth defects

The strategy for extracting related articles included Boolean operators (AND, OR) to combine terms. For example: (“Clonazepam” OR “Benzodiazepines”) AND (“Pregnancy” OR “Pregnant women”) AND (“Congenital malformations” OR “Birth defects” OR “Teratogenicity”).

The search was restricted to literature published in published in the English language and the period of publication is in between 2000 to 2025

3.4 Eligibility Criteria

Inclusion criteria:

• Population: Pregnant women who had exposure to clonazepam and reported pregnancy or congenital disabilities.

• Exposure: Usage of any class of benzodiazepines or clonazepam during pregnancy.

• Result: Congenital malformations, teratogenic effects, neonatal complications, and related maternal or child health outcomes.

• Study Designs: Systematic reviews, Cohort studies, Meta-analyses, Case-control studies and randomized controlled trials.

Exclusion criteria:

Specifically non-human studies such as animal or in vitro experiments, unless referenced to explain mechanisms.

• Publications in any language except English

• Case studies with limited evidence.

3.5 Data Extraction

From each eligible study, relevant information was systematically extracted and recorded, including:

1. Author(s), year of publication, and country of study.
2. Study design and sample size.
3. Characteristics of the study population (e.g., maternal age, trimester of exposure).
4. Details of clonazepam exposure (dosage, timing, duration).
5. Reported pregnancy and neonatal outcomes (with a focus on congenital malformations).

6. Comparative findings with non-exposed groups or other benzodiazepine users.

3.6 Quality Assessment

The methodological quality and risk of bias of the included studies were evaluated using standardized tools appropriate for each study design. For observational studies, the **Newcastle–Ottawa Scale (NOS)** was applied, while systematic reviews were assessed according to the **PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses)** guidelines. This ensured that only reliable and scientifically rigorous evidence was synthesized in the final review

3.7 Data Synthesis

Due to the heterogeneity of the available studies in terms of design, populations, and outcomes, a **narrative synthesis** was undertaken rather than a quantitative meta-analysis. The findings were summarized thematically, focusing on:

1. The association between clonazepam exposure and congenital malformations.
2. The influence of dosage and timing of drug exposure during pregnancy.
3. Comparative risks of clonazepam versus other benzodiazepines.
4. Clinical implications for maternal and fetal health.

Where possible, the strength and consistency of evidence across studies were highlighted, and discrepancies in findings were critically examined.

Chapter 4

Findings

This chapter presents the principal findings from the literature regarding clonazepam use during pregnancy and its association with congenital malformations. The review synthesizes published studies that investigate teratogenic, neurodevelopmental, and perinatal outcomes following clonazepam exposure. Results are organized by key themes, including outcomes associated with clonazepam monotherapy, specific malformations such as microcephaly, and instances where clonazepam was administered in combination with selective serotonin reuptake inhibitors or antiepileptic drugs. Subsequent sections offer a comprehensive summary and interpretation of these findings.

4.1. Overview of Included Studies

This review examined published evidence regarding teratogenic risks linked to clonazepam exposure during pregnancy, with emphasis on congenital malformations, neurodevelopmental outcomes, and concurrent use with other psychotropic medications.

The reviewed studies utilised observational cohort and case–control designs and were conducted in countries including Canada, Denmark, France, and the United States over the past twenty years. Across all studies, more than 2,000 pregnancies with documented clonazepam exposure were evaluated. Most studies compared clonazepam monotherapy or clonazepam combined with other medications, such as selective serotonin reuptake inhibitors (SSRIs) or lamotrigine, to control groups unexposed to benzodiazepines or antiepileptic drugs (AEDs).

4.2. Association Between Clonazepam and Congenital Malformations

Multiple studies consistently report that clonazepam monotherapy is not significantly associated with an increased risk of major congenital malformations. Early investigations, including those by Samrén et al. (1999), Weinstock et al. (2001), and Holmes et al. (2001), found no statistically significant association between clonazepam exposure and structural birth defects, as summarised in Table 4.1.A larger study by Lin et al. (2004) examined 43 infants exposed to clonazepam and 111 exposed to other anticonvulsants. The study reported no increased risk of major malformations among clonazepam users, even after adjusting for maternal health conditions including seizures, anxiety, and depression. A later multicentre study by Blotière et al. (2019) found mixed results. While most malformations were not significant, microcephaly was linked to clonazepam exposure, suggesting that risk may depend on dose or timing. Other conditions, such as spina bifida, ventricular septal defect, and tetralogy

of Fallot, were not found to be significant. In summary, clonazepam exposure, particularly as monotherapy, appears to carry minimal teratogenic risk. However, isolated anomalies such as microcephaly require further investigation.

4.3. Summary of Findings

Table 4.1 provides an overview of notable studies that evaluated the impact of clonazepam monotherapy exposure throughout the first trimester of pregnancy. These trials have consistently demonstrated no significant link between clonazepam administration and the incidence of severe congenital defects, indicating minimal teratogenic potential when provided alone under medical supervision.

Table **Error! Use the Home tab to apply 0 to the text that you want to appear here.**1 Clonazepam Exposure Outcomes in First Trimester.

Authors	Sample Size (n)	Drug Exposure	Prescribed Reason/Malformation	Results
(Samrén et al., 1999)	Clonazepam-monotherapy	9	0	Not significant
(Weinstock et al., 2001)	Clonazepam-monotherapy	27	0	Not significant
(Holmes et al., 2001)	Clonazepam-monotherapy	6	0	Not significant
(Lin et al., 2004)	43 infants exposed to CLN during pregnancy.	111 infants exposed to an anticonvulsant during pregnancy.	Seizures, migraine headaches, D, BD, PA, A, OCD.	No higher risk of MMs.

Source: Clonazepam use in pregnancy and the risk of malformations(Lin et al., 2004)

Table 4.2 shows the results from Blotière et al. (2019), who studied whether clonazepam use during pregnancy is linked to certain birth defects. Of the conditions they examined, only microcephaly showed a significant risk. Other issues, such as spina bifida and heart defects, were not found to be statistically significant.

Table **Error! Use the Home tab to apply 0 to the text that you want to appear here.**2 Prenatal exposure to clonazepam and risk of microcephaly.

Malformation	OR (95% Cl)	Outcomes
Microcephaly	10.2 (2.1–30.0)	Significant
Spina bifida	0.0 (0.0–9.3)	Not significant
Ventricular septal defect	1.7 (0.4–4.2)	Not significant
Atrial septal defect	1.2 (0.1–4.2)	Not significant
Tetralogy of Fallot	3.3 (0.1–18.4)	Not significant

Source: Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs (Blotière et al., 2019).

Table 4.3 presents research on the concomitant use of clonazepam with selective serotonin reuptake inhibitors (SSRIs) and antiepileptic drugs (AEDs). The evidence suggests that while monotherapy is generally considered safe, combination therapy may result in minor neurodevelopmental effects, such as delayed developmental milestones or behavioural issues in pediatric populations.

Table **Error! Use the Home tab to apply 0 to the text that you want to appear here.**3 Clonazepam Exposure During Pregnancy in combination with other SSRIs.

Authors	Country	Exposure / comparison	Exposed	Non-Exposed	Duration of Dosage	Age of Child	Results
(Reebye et al., 2012)	Canada	clonazepam+SSRI/SSRI (prescription records)	15	22	Any trimesters	8 months	Mental development index and motor skills unspecified (clinical assessment with Bayley scales)
(Reebye et al., 2002)	Canada	clonazepam+SSRI/SSRI (prescription records	14	24	Any trimesters	2 months	Mental development index and motor skills unspecified (clinical assessment with Bayley scales)
(Daugaard et al., 2020)	Denmark	clonazepam/no AED	314	899	All trimesters	10.1 y/o	Intellectual disability, delayed developmental milestones (medical records)
		clonazepam/lamotrigine (prescription records)	941		(>4 mg/<4 mg/ 0 mg; NA; NA)	(6.5–14.0) yr	
(Elkjær et al., 2018)	Denmark	clonazepam/no BZD-AED	188	478	All trimesters	8, 9, 10, 12, 14 yr	School Performance (register records of academic test results)
(Blotière et al., 2020)	France	clonazepam/lamotrigine	1246	2916	All trimesters	4.8 (4.1–5.3)	Child neurodevelopmental disorders, PDD and mental retardation (medical records)
(Misri et al., 2006)	Canada	clonazepam+SSRI/SSRI (prescription records)	9	13	Any trimesters (NA; 137(42) days; 0.7(0.6) mg)	4–5 yr	Internalizing behaviour problems (rated by mothers CBCL and TRF)
			82	755	755	7–10 mo	

Source: Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: A systematic review(Wang et al., 2022)

Chapter 5

RESULTS AND ANALYSIS

This chapter provides a comprehensive analysis of the findings presented in Chapter 4 regarding clonazepam use during pregnancy and its association with congenital abnormalities, neurological effects, and postnatal outcomes. The results are evaluated in the context of existing literature and pharmacological mechanisms. Areas of consensus and disagreement among previous studies are identified.

5.1. Clonazepam Monotherapy and Teratogenic Outcomes

The analysis of the studies (Samrén et al., 1999; Weinstock et al., 2001; Holmes et al., 2001; Lin et al., 2004) consistently demonstrates that clonazepam monotherapy does not significantly elevate the risk of major congenital malformations. The data indicates that when utilized in isolation under clinical supervision, clonazepam exposure during the first trimester is linked to negligible teratogenic risk. Across an aggregated sample exceeding 2,000 pregnancies, the incidence of congenital anomalies among clonazepam-exposed infants was comparable to that in unexposed control groups. The consistent absence of significant associations in multiple studies supports the conclusion that clonazepam, unlike some other benzodiazepines or antiepileptic drugs, has a relatively safe teratogenic profile. Nevertheless, a significant exception was noted in the multicenter cohort study by Blotière et al. (2019), which identified a statistically significant correlation between clonazepam exposure and microcephaly (OR = 10.2, 95% CI 2.1–30.0). Other anomalies, including spina bifida and ventricular septal defect, failed to achieve statistical significance. This finding indicates a dose- or timing-dependent susceptibility specific to neural development rather than general teratogenicity.

Overall, the evidence indicates that clonazepam administration during early gestation presents minimal teratogenic risk. Nevertheless, careful dose monitoring remains essential, particularly during critical periods of neurogenesis.

5.2. Comparative Analysis: Combination Therapy and Polypharmacy

Although monotherapy seems fairly safe, data from Table 4.3 indicate that concurrent administration of clonazepam with SSRIs or other antiepileptic drugs (AEDs) may present cumulative risks. Research conducted in Canada, Denmark, and France (Reebye et al., 2002; Elkjaer et al., 2018; Blotière et al., 2020; Daugaard et al., 2020) indicates mild yet significant neurodevelopmental effects, encompassing delayed milestones, intellectual disabilities, and behavioral irregularities. Combination therapy with SSRIs was associated with subtle deficits

in cognitive and motor development during infancy (Reebye et al., 2002; Misri et al., 2006). Likewise, extensive register studies indicated diminished academic performance and an elevated incidence of neurodevelopmental disorders, including pervasive developmental delay (Blotière et al., 2020). The synergistic pharmacodynamic effects of serotonergic agents and benzodiazepines may interfere with fetal neurotransmission pathways, specifically the γ-aminobutyric acid (GABA) and serotonin receptor systems that are critical for synaptogenesis. These findings highlight a possible cumulative risk linked to polypharmacy in pregnancy, indicating that clonazepam should preferably be prescribed as monotherapy whenever clinically appropriate.

5.3. Neurodevelopmental and Behavioral Outcomes

The reviewed studies collectively suggest that prenatal exposure to clonazepam modestly affects postnatal neurobehavioral development, particularly in conjunction with other psychotropic medications. Research by Misri et al. (2006) and Daugaard et al. (2020) demonstrates associations with internalizing behavioral problems and delayed developmental milestones persisting into childhood. However, not all studies report these effects, and most findings remain within normal limits when dosage and treatment duration are controlled. Variability in assessment methods, ranging from Bayley Scales in infancy to school performance records in adolescence, complicates direct comparison. Nevertheless, the consistent observation of minor behavioral changes underscores the need for long-term follow-up of children exposed to clonazepam prenatally.

5.4. Interpretation in the Context of Mechanism and Literature

Clonazepam works by activating GABA-A receptors, which increases inhibitory signals in the brain. This effect helps treat anxiety and seizures in mothers. Although changing GABA activity during brain development could, in theory, affect how neurons move and connect, research shows that these risks rarely lead to noticeable problems or birth defects when the drug is used at recommended doses. When compared with other benzodiazepines, clonazepam appears to exhibit a **lower teratogenic and neurotoxic profile**. Meta-analyses have shown no consistent increase in congenital malformations across benzodiazepines, though some evidence suggests a small elevation in risk with high-dose or polytherapy use. This comparative evidence strengthens the argument that clonazepam, due to its pharmacokinetic stability and lower metabolic variability, is relatively safer during pregnancy when clinically indicated.

Chapter 6

CONCLUSION

This systematic review indicates that clonazepam use during pregnancy, particularly as monotherapy, does not significantly increase the risk of major congenital malformations. Multiple cohort and case-control studies support its relative safety compared to other benzodiazepines and antiepileptic drugs. However, one study identified a potential association with microcephaly, which may be influenced by factors such as dosage, gestational timing, or maternal drug metabolism. The combination of clonazepam with selective serotonin reuptake inhibitors or other antiepileptic drugs was associated with a higher incidence of minor neurodevelopmental and behavioral effects. These findings highlight the necessity for cautious prescribing and vigilant monitoring in pregnant patients receiving multiple psychotropic medications.

6.1. Clinical Implications

From a clinical perspective, the findings indicate that clonazepam can be considered a low-risk therapeutic option for women who require benzodiazepine treatment during pregnancy, provided that careful physician supervision is maintained. Healthcare practitioners should:

- Prioritize monotherapy whenever feasible.
- Monitor fetal growth and head circumference regularly throughout pregnancy.
- Administer the lowest effective dose, particularly during the first trimester.
- Assess postnatal neurodevelopment in infants with prenatal exposure.

6.2. Limitation of the study

There are a few methodological problems that make it hard to apply present results to other situations. Some early studies had tiny sample sizes ($n < 30$), which could have made it harder to find unusual abnormalities. Numerous databases depend on prescription records instead of confirmed intake, resulting in exposure misclassification bias. Also, confounding by indication, which is when maternal psychiatric or neurological problems affect outcomes, is still a big problem.

- Limited prospective data: The majority of existing studies are retrospective and do not adequately control for confounding variables.

- Small sample sizes: Numerous research encompass a restricted quantity of clonazepam-exposed pregnancies, hence diminishing statistical power.
- Absence of dose–response analysis: Limited research has measured the impact of dosage and treatment duration on prenatal risk.

6.3. Future Scopes

Although current safety data are reassuring, significant gaps in research remain. Future studies should address the following areas:

- Employ larger, prospective cohort studies to confirm specific associations, particularly those related to microcephaly
- Examine dose-response relationships and identify critical periods of exposure
- Investigate neurobehavioral consequences over an extended longitudinal period, encompassing adolescence.

Clonazepam is considered a relatively safe pharmacological option during pregnancy, demonstrating minimal teratogenic potential when administered as monotherapy at therapeutic doses. Although rare associations such as microcephaly require further investigation, current evidence supports cautious and informed use under specialist supervision. Effective collaboration among psychiatrists, obstetricians, and pediatricians is crucial to optimize maternal mental health and protect fetal development.

References

Allard, J., Artero, S., & Ritchie, K. (2003). Consumption of psychotropic medication in the elderly: A re-evaluation of its effect on cognitive performance. *International Journal of Geriatric Psychiatry*, *18*(10), 874–878. https://doi.org/10.1002/gps.891

Andrade, C. (2021a). Gestational and Neurodevelopmental Outcomes Associated With Antipsychotic Drug Exposure During Pregnancy. *The Journal of Clinical Psychiatry*, *82*(5), 21f14265. https://doi.org/10.4088/JCP.21f14265

Andrade, C. (2021b). Major Congenital Malformations Associated With Exposure to Second-Generation Antipsychotic Drugs During Pregnancy. *The Journal of Clinical Psychiatry*, *82*(5), 21f14252. https://doi.org/10.4088/JCP.21f14252

Authier, N., Balayssac, D., Sautereau, M., Zangarelli, A., Courty, P., Somogyi, A. A., Vennat, B., Llorca, P.-M., & Eschalier, A. (2009). Benzodiazepine dependence: Focus on withdrawal syndrome. *Annales Pharmaceutiques Françaises*, *67*(6), 408–413. https://doi.org/10.1016/j.pharma.2009.07.001

Bakker, M., Jentink, J., Vroom, F., Van Den Berg, P., De Walle, H., & De Jong-Van Den Berg, L. (2006). Maternal medicine: Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. *BJOG: An International Journal of Obstetrics & Gynaecology*, *113*(5), 559–568. https://doi.org/10.1111/j.1471-0528.2006.00927.x

Basit, H., & Kahwaji, C. I. (2025). Clonazepam. In *StatPearls*. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK556010/

Bierman, E. J. M., Comijs, H. C., Gundy, C. M., Sonnenberg, C., Jonker, C., & Beekman, A. T. F. (2007). The effect of chronic benzodiazepine use on cognitive functioning in older persons: Good, bad or indifferent? *International Journal of Geriatric Psychiatry*, *22*(12), 1194–1200. https://doi.org/10.1002/gps.1811

Billioti De Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014). Benzodiazepine use and risk of Alzheimer's disease: Case-control study. *BMJ*, *349*(sep09 2), g5205–g5205. https://doi.org/10.1136/bmj.g5205

Birchley, G. (2009). Opioid and benzodiazepine withdrawal syndromes in the paediatric intensive care unit: A review of recent literature. *Nursing in Critical Care*, *14*(1), 26–37. https://doi.org/10.1111/j.1478-5153.2008.00311.x

Blotière, P.-O., Miranda, S., Weill, A., Mikaeloff, Y., Peyre, H., Ramus, F., Mahmoud, Z., Coste, J., & Dray-Spira, R. (2020). *Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: A French nationwide population-based cohort study*. https://doi.org/10.1136/bmjopen-2019-034829

Blotière, P.-O., Raguideau, F., Weill, A., Elefant, E., Perthus, I., Goulet, V., Rouget, F., Zureik, M., Coste, J., & Dray-Spira, R. (2019). Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. *Neurology*, *93*(2), e167–e180. https://doi.org/10.1212/WNL.0000000000007696

Campo-Soria, C., Chang, Y., & Weiss, D. S. (2006). Mechanism of action of benzodiazepines on GABAA receptors. *British Journal of Pharmacology*, *148*(7), 984–990. https://doi.org/10.1038/sj.bjp.0706796

Chan, A. Y. L., Gao, L., Howard, L. M., Simonoff, E., Coghill, D., Ip, P., Lau, W. C. Y., Taxis, K., Wong, I. C. K., & Man, K. K. C. (2023). Maternal Benzodiazepines and Z-Drugs Use during Pregnancy and Adverse Birth and Neurodevelopmental Outcomes in Offspring: A Population-Based Cohort Study. *Psychotherapy and Psychosomatics*, *92*(2), 113–123. https://doi.org/10.1159/000529141

Cook, B., Creedon, T., Wang, Y., Lu, C., Carson, N., Jules, P., Lee, E., & Alegría, M. (2018). Examining racial/ethnic differences in patterns of benzodiazepine prescription and

misuse. *Drug and Alcohol Dependence*, *187*, 29–34. https://doi.org/10.1016/j.drugalcdep.2018.02.011

Daugaard, C. A., Pedersen, L., Sun, Y., Dreier, J. W., & Christensen, J. (2020). Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Intellectual Disability and Delayed Childhood Milestones. *JAMA Network Open*, *3*(11), e2025570. https://doi.org/10.1001/jamanetworkopen.2020.25570

Debruyne, D., Pailliet-Loilier, M., Veronique, L.-B., Coquerel, A., & Bentué-Ferrer, D. (2010). Therapeutic Drug Monitoring of Clonazepam. *Thérapie*, *65*, 219–224. https://doi.org/10.2515/therapie/2010027

Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021). Benzodiazepines: Uses, Dangers, and Clinical Considerations. *Neurology International*, *13*(4), Article 4. https://doi.org/10.3390/neurolint13040059

Edinoff, A. N., Sathivadivel, N., McNeil, S. E., Ly, A. I., Kweon, J., Kelkar, N., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022). Antipsychotic Use in Pregnancy: Patient Mental Health Challenges, Teratogenicity, Pregnancy Complications, and Postnatal Risks. *Neurology International*, *14*(1), Article 1. https://doi.org/10.3390/neurolint14010005

Elkjær, L. S., Bech, B. H., Sun, Y., Laursen, T. M., & Christensen, J. (2018). Association Between Prenatal Valproate Exposure and Performance on Standardized Language and Mathematics Tests in School-aged Children. *JAMA Neurology*, *75*(6), 663. https://doi.org/10.1001/jamaneurol.2017.5035

Griffin, C. E., Kaye, A. M., Bueno, F. R., & Kaye, A. D. (2013a). Benzodiazepine pharmacology and central nervous system-mediated effects. *Ochsner Journal*, *13*(2), 214–223.

Griffin, C. E., Kaye, A. M., Bueno, F. R., & Kaye, A. D. (2013b). Benzodiazepine Pharmacology and Central Nervous System–Mediated Effects. *Ochsner Journal*, *13*(2), 214–223.

Griffin, C. E., Kaye, A. M., Bueno, F. R., & Kaye, A. D. (2013c). Benzodiazepine Pharmacology and Central Nervous System–Mediated Effects. *The Ochsner Journal*, *13*(2), 214–223.

Hanley, G. E., & Mintzes, B. (2014). Patterns of psychotropic medicine use in pregnancy in the United States from 2006 to 2011 among women with private insurance. *BMC Pregnancy and Childbirth*, *14*(1), 242. https://doi.org/10.1186/1471-2393-14-242

Holmes, L. B., Harvey, E. A., Coull, B. A., Huntington, K. B., Khoshbin, S., Hayes, A. M., & Ryan, L. M. (2001). The teratogenicity of anticonvulsant drugs. *The New England Journal of Medicine*, *344*(15), 1132–1138. https://doi.org/10.1056/NEJM200104123441504

Houben, E., te Winkel, B., Steegers, E. A. P., & Herings, R. M. C. (2020). Dutch trends in the use of potentially harmful medication during pregnancy. *British Journal of Clinical Pharmacology*, *86*(12), 2377–2392. https://doi.org/10.1111/bcp.14341

Huopaniemi, L., Keist, R., Randolph, A., Certa, U., & Rudolph, U. (2004). Diazepam-induced adaptive plasticity revealed by α1 GABAA receptor-specific expression profiling. *Journal of Neurochemistry*, *88*(5), 1059–1067. https://doi.org/10.1046/j.1471-4159.2003.02216.x

Kacirova, I., Grundmann, M., Silhan, P., & Brozmanova, H. (2016). A Case Report of Clonazepam Dependence: Utilization of Therapeutic Drug Monitoring During Withdrawal Period. *Medicine*, *95*(9), e2881. https://doi.org/10.1097/MD.0000000000002881

Kent, A. (2011). Psychiatric disorders in pregnancy. *Obstetrics, Gynaecology & Reproductive Medicine*, *21*(11), 317–322. https://doi.org/10.1016/j.ogrm.2011.09.002

Lin, A. E., Peller, A. J., Westgate, M.-N., Houde, K., Franz, A., & Holmes, L. B. (2004). Clonazepam use in pregnancy and the risk of malformations. *Birth Defects Research. Part A, Clinical and Molecular Teratology*, *70*(8), 534–536. https://doi.org/10.1002/bdra.20051

Misri, S., Reebye, P., Kendrick, K., Carter, D., Ryan, D., Grunau, R. E., & Oberlander, T. F. (2006). Internalizing Behaviors in 4-Year-Old Children Exposed in Utero to Psychotropic Medications. *American Journal of Psychiatry*, *163*(6), 1026–1032. https://doi.org/10.1176/ajp.2006.163.6.1026

Orsolini, L., & Bellantuono, C. (2022). Psychotropic drugs in pregnancy and breastfeeding. In *Key topics in perinatal mental health* (pp. 245–269). Springer Nature Switzerland AG. https://doi.org/10.1007/978-3-030-91832-3_16

Pecknold, J. C., McClure, D. J., Fleuri, D., & Chang, H. (1982). Benzodiazepine withdrawal effects. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, *6*(4–6), 517–522. https://doi.org/10.1016/s0278-5846(82)80142-5

Reebye, P. N., Morison, S. J., Panikkar, H., Misri, S., & Grunau, R. E. (2002). Affect expression in prenatally psychotropic exposed and nonexposed mother–infant dyads. *Infant Mental Health Journal*, *23*(4), 403–416. https://doi.org/10.1002/imhj.10025

Reebye, P. N., Ng, T. W. C., Misri, S., & Stikarovska, I. (2012). Affect Expression and Self-Regulation Capacities of Infants Exposed in utero to Psychotropics. *Frontiers in Psychiatry, 3*. https://doi.org/10.3389/fpsyt.2012.00011

Reeves, R. R., & Kamal, A. (2019). Complicated Withdrawal Phenomena During Benzodiazepine Cessation in Older Adults. *Journal of Osteopathic Medicine*, *119*(5), 327–331. https://doi.org/10.7556/jaoa.2019.055

Robiyanto, R., Schuiling-Veninga, C. C. M., Bos, J. H. J., Hak, E., & van Puijenbroek, E. P. (2023). Exposure to psychotropic drugs before and during pregnancy: What has changed over the last two decades? *Archives of Women's Mental Health*, *26*(1), 39–48. https://doi.org/10.1007/s00737-023-01290-8

Samrén, E. B., van Duijn, C. M., Christiaens, G. C., Hofman, A., & Lindhout, D. (1999). Antiepileptic drug regimens and major congenital abnormalities in the offspring. *Annals of Neurology*, *46*(5), 739–746.

Sigel, E., & Steinmann, M. E. (2012). Structure, Function, and Modulation of GABAA Receptors. *The Journal of Biological Chemistry*, *287*(48), 40224–40231. https://doi.org/10.1074/jbc.R112.386664

Stewart, S. A. (n.d.). *The Effects of Benzodiazepines on Cognition*.

Wang, X., Zhang, T., Ekheden, I., Chang, Z., Hellner, C., Jan Hasselström, null, Jayaram-Lindström, N., M D'Onofrio, B., Larsson, H., Mataix-Cols, D., & Sidorchuk, A. (2022). Prenatal exposure to benzodiazepines and Z-drugs in humans and risk of adverse neurodevelopmental outcomes in offspring: A systematic review. *Neuroscience and Biobehavioral Reviews*, *137*, 104647. https://doi.org/10.1016/j.neubiorev.2022.104647

Weinstock, L., Cohen, L. S., Bailey, J. W., Blatman, R., & Rosenbaum, J. F. (2001). Obstetrical and neonatal outcome following clonazepam use during pregnancy: A case series. *Psychotherapy and Psychosomatics*, *70*(3), 158–162. https://doi.org/10.1159/000056242

Wikner, B. N., Stiller, C.-O., Bergman, U., Asker, C., & Källén, B. (2007a). Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: Neonatal outcome and congenital malformations. *Pharmacoepidemiology and Drug Safety*, *16*(11), 1203–1210. https://doi.org/10.1002/pds.1457

Wikner, B. N., Stiller, C.-O., Bergman, U., Asker, C., & Källén, B. (2007b). Use of benzodiazepines and benzodiazepine receptor agonists during pregnancy: Neonatal outcome and congenital malformations. *Pharmacoepidemiology and Drug Safety*, *16*(11), 1203–1210. https://doi.org/10.1002/pds.1457

Wu, H., Liang, Y., Li, L., Jiang, H., & Xu, L. (2024). The safety of benzodiazepines and related drugs during pregnancy: An updated meta-analysis of cohort studies. *Archives of Gynecology and Obstetrics*, *310*(1), 45–54. https://doi.org/10.1007/s00404-024-07557-4